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Abstract
The nonstructural protein 1 (NS1) of influenza A virus (IAV) enables the virus to disarm the host cell type 1 IFN defense
system. Mutation or deletion of the NS1 gene leads to attenuation of the virus and enhances host antiviral response making
such live-attenuated influenza viruses attractive vaccine candidates. Sublingual (SL) immunization with live influenza virus
has been found to be safe and effective for inducing protective immune responses in mucosal and systemic compartments.
Here we demonstrate that SL immunization with NS1 deleted IAV (DeltaNS1 H1N1 or DeltaNS1 H5N1) induced protection
against challenge with homologous as well as heterosubtypic influenza viruses. Protection was comparable with that
induced by intranasal (IN) immunization and was associated with high levels of virus-specific antibodies (Abs). SL
immunization with DeltaNS1 virus induced broad Ab responses in mucosal and systemic compartments and stimulated
immune cells in mucosa-associated and systemic lymphoid organs. Thus, SL immunization with DeltaNS1 offers a novel
potential vaccination strategy for the control of influenza outbreaks including pandemics.
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Introduction
Infection with influenza type A viruses causes annual epidemics
with potential to develop into pandemics affecting hundreds
millions worldwide. Vaccination against influenza is a key tool for
controlling influenza epidemics and pandemics. Currently, only
intramuscular (IM) formaldehyde and propionolactone-inactivated
and IN cold-adapted attenuated vaccines are licensed in humans
[see reviews [1,2,3]]. The efficacy of both types of vaccines has
been reported to be comparable in adults [4]. However, live-
attenuated influenza vaccines (LAIV), apart from the convenience
of their administration appear to induce longer-lasting and
broader cross-protective immunity than corresponding inactivated
vaccines [4,5,6,7,8,9].
Although cold-adapted influenza vaccines (CAIVs) are safe
and approved for human use the precise genetic and molecular
mechanisms of attenuation based on single mutations are not
completely understood [10,11] CAIVs are capable to replicate in
humans and especially in children for several days [12]. Genetic
stability of CAIV is hard to predict since viruses re-isolated from
immunized hosts often reveal a different set of point mutations as
compared to that of original vaccine viruses [12]. An alternative
approach based on reverse genetics to obtain influenza viruses
containing modifications in the NS1 gene has been developed
[13]. NS1 deleted viruses (DeltaNS1) lacking the NS1 protein-
dependent alpha/beta interferon (IFN-a/b) antagonist function
[13,14] are genetically stable and are replication-deficient in
IFN-competent hosts. Importantly, such viruses are capable of
inducing protection in mice [15,16], ferrets and non-human
primates [17]. Moreover, DeltaNS1 vaccine candidate is well-
tolerated, safe and immunogenic in healthy volunteers [18]. Due
to the lack of the entire NS1 cistron in DeltaNS1 viruses, this
mutation cannot be compensated for by any suppressor mutation
and, unlike LAIV, DeltaNS1 virus re-isolation from immunized
hosts is rare and at most limited to early time-points after
immunization supporting the notion that replication of DeltaNS1
virus is essentially abortive [18].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39921Delivery of LAIV via the IN (spray, drops) and pulmonary
(aerosol delivery) routes targets the nasopharynx-associated
lymphoid tissue (NALT) and the lung mucosa, respectively. Such
formulations induce protective immunity against influenza virus
[7,19]. However, post-licensure surveillance studies of a nasal
killed influenza vaccine adjuvanted with Escherichia coli heat-labile
enterotoxin identified a possible association with rare but severe
cases of Bell’s palsy [20]. The sublingual (SL) (under the tongue)
Figure 1. SL Immunization with Delta H5N1 induces homotypic and heterosubtypic immunity. BALB/c mice were immunized with
different doses of Delta H5N1 (m H5N1) or wt live virus A/PR8/34 (PR8) H1N1 via the sublingual (SL), nasal (N) or intranasal (IN) route. Four weeks later,
the mice were IN challenged with homotypic A/Aquatic bird/Korea/W81/2005 (H5N2) (Fig. 1A) or heterosubtypic A/PR8 (H1N1) (Fig. 1B) as described
in Materials and Methods. Morbidity and mortality were monitored daily for at least 3 weeks. Mean body weight 6 SD of each experimental group of
5–10 mice was determined at each indicated time point. Mortality is expressed as mean % 6 SD of mice that survived the challenge. The values are
the means of 5–10 mice per group.
doi:10.1371/journal.pone.0039921.g001
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delivery of drugs because proteins and/or peptides are not
subjected to the degradation as opposed to oral administration
that delivers agents directly to the upper gastrointestinal tract. SL
delivery of antigen has proven effective for administering protein
allergens [21]. Recently, we have shown that administration of
inactivated and even live influenza virus via the SL route did not
redirect the viruses to the central nervous system (CNS) [22].
Thus, the SL route confers substantial safety advantages for
mucosal delivery of influenza virus vaccines. Furthermore, SL
administration of non-replicating antigens, including inactivated
influenza virus induces broad-spectrum immune responses in the
airway and genital mucosa, as well as in extra-mucosal tissues
(blood, peripheral lymph nodes, and spleen) [22,23,24]. The
induced immune responses comprise serum and secretory
antibody (Ab) responses and pulmonary effector cytotoxic T
lymphocyte (CTL) responses. Importantly, SL is effective in
inducing so called heterosubtypic immunity (HSI), the cross-
protection against infection by a subtype different from the
immunizing one [22]. Although initial antigen uptake by SL
dendritic cells (DC) and their subsequent migration and antigen-
presentation occur in draining cervical lymph nodes (CLN) [25],
the inductive mechanisms of SL immunization remain to be
elucidated.
It is generally accepted that live-attenuated vaccines induce
better HSI than injectable killed vaccines [4,5,6,7,8,9,26,27].
Attempts to generate vaccines that include IAV conserved proteins
for induction of HSI have been made [28,29,30,31], but no HSI
vaccine is currently available. In this study we evaluated the effect
of a novel vaccination strategy that combines a newly developed
replication-deficient influenza virus - DeltaNS1 - and an
alternative mucosal delivery route - SL - for induction of broad
protection against infection with different influenza virus subtypes.
The mechanisms by which SL immunization with influenza
induces specific immune responses in different lymphoid organs
were explored.
Materials and Methods
DeltaNS1 Viruses
Generation of A/PR8 DeltaNS1 (DeltaH1N1) virus was
described in detail elsewhere [14,16]. To obtain a high virus titer
infected Vero cell supernatant was ultrracentrifuged (Beckmann
L80 Ultracentifuge SW 32Ti rotor) at 32,000 rpm (125,7506g)
through a 30% sucrose/SPGN buffer cushion (30% sucrose;
75 mM NaCl; 3,8 mM KH2PO4; 7,2 mM K2HPO4, 4,9 mM L-
Glutamat; pH 7,5) for 2 hr at 4uC and the purified virus pellet was
resuspended in SPGN buffer containing 6% sucrose. The final
virus titer was 10
9,4 TCID50/ml.
The A/Vietnam/1203/04 DeltaNS1 (Delta H5N1) virus was
obtained by reverse genetics in Vero cells [17], as a 5:3 reassortant,
encoding four proteins, namely hemagglutinin (HA), neuramini-
dase (NA), M1, and M2 of the A/Vietnam/1203/04 (H5N1) virus
while the remaining genes were derived from the IVR-116
reassortant vaccine strain distributed by the World Health
Organization (WHO).The IVR-116 inherited HA and NA genes
from influenza A/New Caledonia/20/99 (H1N1), the PB1 gene
from A/Texas/1/77 (H3N2), and all other genes from the A/
Puerto Rico/8/34 (H1N1) (PR8) virus. The HA cleavage site was
modified in a trypsin-dependent manner complementing the
deleted NS1 gene as an attenuation factor. The DelNS1 H5N1
virus was able to grow in serum-free Vero cell cultures to a high
titer of 10
8,2 TCID50/ml. Both delNS1 viruses were replication-
deficient in interferon-competent cells and were not shed in
immunized animals.
Viruses
Egg-grown influenza virus strains A/PR/8/34 (H1N1) (A/
PR8), A/Philippines/2/82/X-79 (H3N2) (A/Philippines) were
prepared as previously reported [32]. Mouse-adapted viruses A/
PR8 and A/Philippines prepared as lung homogenates of IN
infected mice were used for challenge as previously described [32].
The A/Aquatic bird/Korea/W81/2005 (H5N2), isolated from
wild bird in Korea in 2006, kindly provided by Dr. Young-Ki
Figure 2. Induction of virus-specific IgG and IgA upon
immunization with Delta H5N1. BALB/c mice were immunized
with different doses of Delta H5N1 (m H5N1) or wt live virus A/PR8/34
(PR8) H1N1 via the sublingual (SL), nasal (N) or intranasal (IN) route. Four
weeks later sera were collected and the levels of H5N1 virus-specific IgG
and IgA were determined by Delta H5N1 virus-coated ELISA plates. The
values represent the mean + SEM (vertical bars) end point ELISA
antibody titers determined on 5 mice per group.
doi:10.1371/journal.pone.0039921.g002
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passages (15 times) in BALB/c mice. After final passage, single
plaque was isolated by three consecutive plaque purifications on
MDCK cells, amplified in embryonated chicken eggs, and the
LD50 of the H5N2 virus was determined in mice for challenge
experiment.
Figure 3. Induction of homotypic and HSI upon immunization with Delta H1N1. BALB/c mice were immunized IN or SL with different doses
of Delta H1N1 (mH1N1), given once (1x) or twice (2x) at 2-week intervals. Four weeks later, animals were intranasally challenged with 56LD50 of
homologous mouse-adapted A/PR8 (Fig. 3A) or heterosubtypic mouse-adapted A/Philippines (A/P) H3N2 (Fig. 3B) virus. Morbidity and mortality were
monitored daily. Data are expressed as mean (body weight or % survival) determined on groups of 5–10 mice.
doi:10.1371/journal.pone.0039921.g003
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Female BALB/c mice aged 6–8 weeks were purchased from
Orient Bio Inc. (Orient Inc, Korea). All mice were maintained in
specific pathogen–free barrier facilities. A/PR8-hemagglutinin
(HA-TCR) transgenic mice, prepared as previously described [33],
were bred in International Vaccine Institute animal facility. All
experiments and animal procedures conformed to protocols
approved by the Institutional Animal Care and Use Committees
at International Vaccine Institute (2010-017) and Yonsei Univer-
sity (2010-00-32619), Seoul, Korea.
Cell Lines
Madin-Darby canine kidney (MDCK) cells (ATCC, Manassas,
VA), were maintained in standard complete Dulbecco’s modified
Eagle’s medium (D-MEM) (Gibco, Grand Island, NY) containing
5% fetal bovine serum (FBS) and antibiotics.
Immunization
For SL immunization, 5 ml of vaccine were placed underneath
the tongue of ketamine-anesthetized mice using micropipette. The
procedure was repeated 4 times in 5-minute interval to deliver the
total of 20 ml of vaccine per mouse per immunization. Mice were
kept with heads placed in ante flexion for 30 minutes after the
immunization before being returned back to the cages. For IN and
nasal (N) immunization, each ketamine-anesthetized mouse re-
ceived a total of 50 ml (25 ml per each nostril) or 10 ml( 5ml per
each nostril) of vaccine, respectively. The vaccine doses are
specified in Figure legends.
Infection with Influenza Viruses
Fifty percent lethal dose (LD50) was determined by inoculating
groups of eight mice intranasally with serial 10-fold dilutions of
virus as previously described [34]. For infection, ketamine-
anesthetized mice were inoculated intranasally with a lethal dose
with 56LD50 of A/PR/8/34 (H1N1), A/Philippines (H3N2), or
A/Aquatic bird/Korea/W81/2005 (H5N2) viruses resuspended
in 50 ml PBS per animal.
Hemagglutination-inhibition (HI) Assay
Samples were treated with receptor destroying enzyme II (RDE,
Denka Seiken Co., Ltd., Tokyo, Japan) at a final dilution of 1:3
before being tested in HI assay. Two-fold serially diluted samples
were incubated with equal volume containing 100 TCID50 of
viruses in V shaped-bottom 96-well microtiter plates at 37uC for
1 h. At the end of incubation, freshly prepared 1% chicken red
blood cells (CRBC) were added, and plates were mixed by
agitation, covered, and allowed to set for 1 h at 4uC temperature.
The HI titers were determined by the reciprocal of the last dilution
which contained non-agglutinated CRBC. Positive and negative
control samples were included on each plate.
ELISA
The standard ELISA was performed for detection of virus-
specific Abs in the sera and secretions. 96-well MaxiSorp
TM Nunc-
Immuno plates (Nalgene Nunc International, Naperville, IL) were
coated overnight with inactivated virus at a concentration of 5 mg/
ml. Dilutions of specimens were incubated 2 h on coated and
blocked ELISA plates. Bound immunoglobulins were detected
with goat anti-mouse Ig (H+L) horseradish peroxidase-conjugated
antibody (Southern Biotechnologies Associates, Inc., Birmingham,
AL). At the end of the incubation (2 h at 37uC), tetramethylben-
zidine (TMB) substrate was added and the reaction was stopped
with an equal volume of 1 M sulfuric acid. The color developed
was measured in a SPECTRAmax photometer at 450 nm. The
reproducibility of the assay was ascertained by applying a control
hyperimmune mouse serum on each plate. Assay results were
Figure 4. Induction of HI Abs upon immunization with Delta
H1N1. On the day before challenge as described in Figure 3, the sera
were collected and the titers of HI Abs were determined against A/PR8
virus. The values represent the mean + SEM antibody titers of sera from
5 mice per group.
doi:10.1371/journal.pone.0039921.g004
Figure 5. Induction of virus-specific Abs upon immunization
with Delta H1N1. On the day before challenge as described in
Figure 3, the sera were collected and the titers of virus-specific Abs
were determined by A/PR8 virus-coated ELISA plates. The values
represent the mean + SEM antibody titers of sera from 5 mice per
group.
doi:10.1371/journal.pone.0039921.g005
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the last dilutions that are above cutoff for assay (OD 450 nm
reaches plateau).
In vivo Lymphocyte Proliferation Assay
Hemagglutinin (HA)-specific CD4
+ T cells were isolated from
all lymph nodes of HA-TCR transgenic mice of BALB/c
background using MACS beads (Miltenyi Biotec, Auburn, CA).
The HA-specific CD4
+ T cells were labeled with CFSE
(Invitrogen, Carlsbad, CA) according to manufacturer’s manual.
A total of 1.8610
7 CFSE labeled cells were intravenously
transferred to BALB/c. Next day the recipients were immunized
sublingually with 2610
7 pfu of Delta H1N1, 2610
5 pfu of mouse-
adapted wt live or 40 mg of formalin-inactivated A/PR8. Three
days later, proliferation of transferred CD4
+ T cells isolated from
different lymphoid tissues was visualized by FACS analysis of their
CFSE profile on BD FACS Calibur Flow Cytometer (BD
Biosciences, San Jose, CA).
Statistics
The data are expressed as the mean 6 one standard error of the
mean (SEM) and compared using a two-tailed student’s t-test or an
unpaired Mann Whitney U test available in Microsoft Excel
software (Redmond, WA).
Results
SL Immunization with DeltaNS1 Viruses Induces
Protection against Homotypic and Heterosubtypic
Challenge
Two live-attenuated influenza A virus vaccine candidates that
have deleted nonstructural protein NS1 gene, the A/Vietnam/
1203/04 DeltaNS1 (Delta H5N1) and A/PR8 DeltaNS1 (Delta
H1N1) mutants, were examined in this study.
We first tested the immunogenicity of Delta H5N1 vaccine
candidate as it would be stockpiled for use in the event of H5N1
influenza outbreak. As shown in Figure 1, a single SL immuni-
zation with Delta H5N1 subtype induced complete protection
against infection with mouse-adapted A/Aquatic bird/Korea/
W81/2005 (H5N2) which shares 94.4% nucleotide sequence
homology with HA of highly pathogenic avian influenza virus A/
VN1203 (H5N1) and Delta H5N1 viruses (Fig. 1A). The level of
protection is comparable with that seen in mice immunized with
the vaccine given through IN route. When lethally challenged with
heterosubtype A/PR8 H1N1, 80% of Delta H5N1 immunized
survived (Fig.1B). Of note, NAs of A/PR8 H1N1 and A/VN1203
H5N1 share 84% amino acid sequence identity and considered
significantly drifted. Results suggest that single SL immunization
with replication-deficient influenza A viruses H5N1 lacking the
NS1 gene induced complete protection against challenge with
drifted virus and high level of HSI. Protection was associated with
antigen-specific IgG Ab levels in blood (Fig. 2). Although the dose
used for SL immunization was significantly higher than that used
for N or IN immunization, it is important that SL immunization
with DelNS1 viruses induced antigen specific IgG at levels
comparable to those induced by administration of the vaccine to
different sites of the respiratory tract, a finding which is consistent
with earlier reports [32,35].
Figure 6. Levels of virus-specific IgG induced in mucosal and
systemic compartments upon immunization with DeltaNS1
IAV. BALB/c mice were immunized with different doses of Delta H1N1
(m H1N1) or wt live virus A/PR8/34 (PR8) H1N1 (WT) via the sublingual
(SL) or intranasal (IN) route. Four weeks later, titers of H1N1 (A/PR8)
virus-specific IgG in sera and secretions were determined by ELISA. The
values represent mean + SEM ELISA titers determined on groups of
5 mice.
doi:10.1371/journal.pone.0039921.g006
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PR8 Delta H1N1 vaccine since A/PR8 (H1N1) and A/Philippines
(H3N2) viruses are common laboratory mouse-adapted influenza
strains. Four weeks after a single SL immunization with Delta
H1N1, mice were challenged with homologous A/PR8 (H1N1) or
heterosubtypic A/Philippines (H3N2) virus. As shown in Fig. 3A,
80% of SL immunized mice survived a lethal challenge with
mouse-adapted homologous A/PR8 (H1N1). When challenged
with heterosubtypic A/Philippine (H3N2) viruses, 60% of
immunized mice recovered from the lethal infection (Fig. 3B).
However, complete protection (100%) against homotypic and
heterosubtypic challenges was readily achieved by a SL booster
immunization given two weeks after primary immunization
(Fig. 3A and 3B). Likewise, SL or IN immunization with a sublethal
dose of mouse-adapted virus A/PR8 (H1N1), or IN immunization
with Delta H1N1 induced complete protection against homotypic
and heterosubtypic challenge, in keeping with previous reports
[17,22,32]. Thus, either a single IN immunization or 2 SL
immunizations with Delta H1N1 induced complete protective
homotypic and HSI. Protection was associated with levels of HI
Abs in blood (Fig. 4) and virus-specific Abs (Fig. 5), as the second
SL immunization with Delta H1N1 boosted effectively Ab
responses to levels comparable to those induced by wild type
(wt) viruses or IN immunization with Delta H1N1.
SL Immunization with DeltaNS1 IAV Induces Mucosal and
Systemic Ab Responses
Since Ab responses play an important role in protection against
challenge with same subtype by virus neutralization as well as in
HSI [32,36], we examined whether SL immunization with live
attenuated DeltaNS1 IAV induced virus-specific antibody re-
sponses. As shown in Fig. 6, single SL immunization with live
attenuated DeltaNS1 IAV (H1N1) induced significant levels of
virus-specific IgG in blood, lungs and nasal washes 4 weeks after
immunization. SL immunization induced lower levels of virus-
specific IgG in blood and nasal washes as compared to IN
immunization with the same vaccine or SL immunization with
a sublethal dose of wt live virus. However, levels of virus-specific
IgG induced in the lungs after SL immunization were comparable
to those induced by other immunization routes with the same
vaccine or immunization with a sublethal dose of wt live virus.
Virus-specific IgA levels induced by SL immunization with
DeltaNS1 IAV were lower compared to those induced by N or
IN immunization with the same vaccine or SL immunization with
a sublethal dose of wt live virus (Fig. 7). Of note, levels of virus-
specific IgA induced in the lungs but neither in the nasal cavity nor
in blood correlated with protection. These results indicate that the
virus-induced specific Ab levels provide a correlate of vaccine
efficacy against lethal challenge.
SL Immunization with DeltaNS1 IAV Activates Immune
Cells in Mucosa-associated and Systemic Lymphoid
Organs
To better understand the mechanisms whereby SL immuniza-
tion induces broad mucosal and systemic immune responses, we
conducted adoptive transfer experiments as schematically illus-
trated in Figure 8. CD4
+ T cells isolated from HA-TCR transgenic
mice were labeled with CFSE and adoptively transferred to naı ¨ve
mice. One day later, recipients were given a single SL dose of
Figure 7. Levels of virus-specific IgA induced in mucosal and
systemic compartments upon immunization with DeltaNS1
IAV. BALB/c mice were immunized as described in Figure 6. Four weeks
later, titers of H1N1 (A/PR8) virus-specific IgA in sera and secretions
were determined by ELISA. The values represent mean + SEM ELISA
titers determined on groups of 5 mice.
doi:10.1371/journal.pone.0039921.g007
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activity of mononuclear cells from lungs, cervical lymph nodes
(CLN), mediastinal (MdLN) and spleens was analyzed by flow
cytometry. Proliferating HA-TCR transgenic CD4
+ T cells were
observed in all lymph nodes analyzed, including MdLN. The
proliferative activitiy of lymph node cells was comparable in SL
immunized mice given either wt live virus or inactivated vaccine.
These results demonstrate that SL DeltaNS1 IAV efficiently
Figure 8. SL immunization with DelNS1 vaccine activates mucosal and extramucosal CD4+ T cells. CFSE-labeled CD4
+ T cells from HA-
TCR transgenic mice were adoptively transferred into naı ¨ve mice. One day later, recipients were given SL 2610
7 pfu of Delta H1N1, 2610
5 pfu of
mouse-adapted wt live or 40 mg of formalin-inactivated A/PR8. Three days after the immunization, proliferating (CFSE stained) HA-TCR CD4
+ T cells
were detected in cervical lymph nodes (CLN), lungs, mediastinal lymph nodes (MdLN) and spleens by FACS analysis. The data are representative of
two experiments showing similar results.
doi:10.1371/journal.pone.0039921.g008
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systemic lymphoid organs resulting in initiation and recall of
immune responses in these tissues.
Discussion
In this study we provide proof-of-concept that a novel influenza
vaccination strategy using the SL route for delivery of live-
attenuated replication-deficient influenza virus that lacks the entire
NS1 gene induced protective immunity against infection by the
same or a different virus subtype. Indeed, we found that a single
SL immunization readily induced protection against infection with
the same subtype, however two immunizations were required for
inducing complete protection against challenge by a different
subtype. Protection was comparable to that seen after infection
with a sublethal dose of wt virus. These results are consistent with
our previous findings showing that SL immunization with
a sublethal dose of wt live virus induced both homotypic and
HSI [22]. In the current study, partial HSI induced by a single SL
immunization suggests that virus replication competence may play
a role in protection induced by the vaccine. It is interesting that
Delta H5N1 seems to be more effective for inducing protective
immunity against heterosubtypic H1N1 virus challenge. The
finding is supported by recent study showing that hen egg yolk Abs
(IgY) raised against H5N1 whole inactivated virus recognize
conserved epitopes present in both virus types H5N1 and H1N1
and provide cross-protection against infection with H1N1 virus. In
contrast, IgY raised against H1N1 whole inactivated virus
recognize only type-specific protective epitopes that are capable
of protecting only against different strains of H1N1 but not against
H5N1 [37]. The molecular basis of these findings is not clear and
should be addressed in future studies.
Protection induced by SL Delta NS1 virus was associated with
serum HI Ab levels and virus-specific Ab titers in systemic and
mucosal compartments. Even within a group of mice that received
a single SL immunization, only animals who developed high levels
of serum virus-specific Abs survived a lethal challenge (data not
shown). Moreover, a single SL immunization with DeltaNS1 virus
induced incomplete and variable levels of protection against
homologous and heterologous challenges. These observations
indicate that SL application of liquid vaccine may not consistently
distribute virus particles onto the SL mucosa and/or could be
influenced by the presence variable amounts of saliva from animal
to animal. Although SL immunization required significantly
higher doses of the vaccine given at relatively higher concentra-
tions (application volumes are limited to a few ml) to achieve levels
of protective immunity comparable to IN immunization, our
findings indicate that SL immunization is an attractive option for
non-invasive delivery of DeltaNS1 vaccine. Further studies in
primates and humans are warranted, especially given the fact that
live attenuated vaccines may show comparable immunogenicity
after oral or IN administration in humans [38]. Optimal
formulation of the vaccine for SL application needs to be
developed to facilitate consistent retention and uptake of the virus
while reducing the dose.
In addition, SL DeltaNS1 vaccine was as immunogenic and
protective as mouse-adapted live virus given by the same route.
Furthermore, SL immunization with DeltaNS1 induced broad
virus-specific IgG and IgA Ab responses in blood, lung and nasal
washes. The latter findings are in keeping with our previous
observations that the SL mucosa is an efficient site for induction of
broad-spectrum mucosal and systemic immune responses [23,24]
to a variety of antigens, including live or inactivated influenza virus
[22].
In an attempt to elucidate the mechanisms governing induction
of protective immune responses by SL immunization, we
conducted a study on the role of resident antigen-presenting cells
(APC) as potential factors in initiating immunity to SL antigens.
We have shown previously that briefly after SL administration,
dendritic cells (DC) in SL mucosa captured the antigen and
migrated to CLN, where they share the processed antigen with
resident DC to initiate antigen-specific immune responses. The
process is dependent on CCR7-CCL19/CCL21 pathway [25]. In
current study we adapted adoptive transfer experiments and found
that SL administration of DeltaNS1 virus stimulates antigen-
specific proliferation of immune cells in local and distant mucosa-
associated and systemic lymphoid tissues. This was also true for
both inactivated and wt live viruses. These findings suggest that
the SL mucosa is an effective mucosal immune inductive site and
that resident APCs in SL mucosa play an important role in the
initiation and recall of broad immune responses. The precise role
for SL DC subsets in induction of broad immune response is being
investigated in our laboratory.
It is unlikely that SL administration of our live attenuated
replication-deficient DeltaNS1 vaccine redirects the vaccine virus
to the CNS since neither inactivated nor live virus was detected in
olfactory bulbs after SL immunization [22]. The safety of SL
immunization is further supported by our observation that SL
application of as many as 2610
5 pfu of mouse-adapted A/PR8
virus (4,000 LD50) did not induce appreciable body weight loss or
mortality in mice. In marked contrast, all mice succumbed to an
IN application of as few as 250 pfu of the virus (5LD50). The safety
of the CAIV is based on a large number of point mutations
distributed across the internal gene segments. However, only
a small number of mutations localized in the polymerase genes are
responsible for the attenuation of cold-adapted virus strains that
are unable to replicate at normal body temperature [10,11]. The
genetic stability of CAIV strains or other promising temperature-
sensitive vaccine candidate strains is often questioned since viruses
re-isolated from vaccinated hosts reveal additional point mutations
that might eventually function as "suppressor" mutations even
causing enhanced replication properties and a possible loss of the
temperature-sensitive phenotype [11,13,39,40,41]. On the other
hand, DeltaNS1 vaccine construct is genetically stable and
replication-deficient in IFN-competent hosts [16,18]. Obviously,
a large deletion or lack of the entire NS1 cistron (delNS1virus)
cannot be compensated for by any suppressor mutation. The high
immunogenicity of live replication-deficient vaccines combined
with the lack of vaccine virus shedding makes the DeltaNS1 virus
a promising influenza vaccine candidate.
Thus, our study demonstrates that SL administration of
DeltaNS1 vaccine, aside from being safe and easy to administer,
can induce broad heterosubtypic immunity against influenza A
viruses of different subtypes. This novel vaccination strategy based
on SL administration of highly immunogenic replication-deficient
DeltaNS1 virus does not require special delivery devices nor
trained healthcare personnel and hence offers a promising option
for the control of influenza outbreaks including pandemics.
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